Bleselumab
Bleselumab is a monoclonal antibody that is being investigated for its potential use in preventing organ rejection in transplantation. It is a humanized antibody that targets the CD40 receptor, which plays a crucial role in the activation of the immune system.
Mechanism of Action[edit]
Bleselumab functions by binding to the CD40 receptor on B cells and other antigen-presenting cells. The CD40 receptor is involved in the activation and differentiation of B cells, as well as in the activation of T cells. By inhibiting the interaction between CD40 and its ligand, CD40L, bleselumab can suppress the immune response that leads to organ rejection. This makes it a promising candidate for use in immunosuppressive therapy following organ transplantation.
Clinical Development[edit]
Bleselumab is currently undergoing clinical trials to evaluate its safety and efficacy in preventing organ rejection. These trials are focused on patients who have received kidney transplants, as the drug aims to reduce the need for traditional immunosuppressive drugs, which can have significant side effects.
Potential Benefits[edit]
The use of bleselumab in transplantation could offer several benefits over existing therapies. By specifically targeting the CD40 pathway, it may provide a more targeted approach to immunosuppression, potentially reducing the risk of infection and other complications associated with broad-spectrum immunosuppressive drugs. Additionally, it may help in reducing the incidence of chronic rejection, a major cause of long-term graft loss.
Challenges and Considerations[edit]
While bleselumab shows promise, there are challenges that need to be addressed in its development. These include ensuring that the drug does not overly suppress the immune system, which could lead to increased susceptibility to infections and malignancies. Additionally, long-term studies are needed to fully understand the effects of CD40 inhibition on the immune system and overall patient health.
Related Pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian


